| Title | Treatment | Disease | Phase | Enrollment | Status | National Clinical Trials Database Number |
|---|---|---|---|---|---|---|
| Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | Ipilimumab | Sarcoma, Wilm tumor, lymphoma, neuroblastoma | 1 | 33 | Completed (November 2013) | NCT01445379 |
| Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma | Ipilimumab | Melanoma | 2 | 14 | Completed (July 2016) | NCT01696045 |
| Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | Nivolumab | Refractory or recurrent hypermutated malignancies, biallelic mismatch repair deficiency positive patients | 1/2 | 20 | Accruing (Start date May 2017) | NCT02992964 |
| A Phase I/II Clinical Trial of Nivolumab in Progressive/Relapsed Pediatric Solid Tumors | Nivolumab | Osteosarcoma, Ewing sarcoma, neuroblastoma, rhabdomyosarcoma | 1/2 | 30 | Not yet accruing (Posted September 2016) | NCT02901145 |
| Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies | Nivolumab ± ipilimumab | High grade primary CNS malignancies | 2 | 170 | Accruing (Start date June 2017) | NCT03130959 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | Nivolumab + lirilumab | Refractory or recurrent malignancies | 1/2 | 397 | Accruing (Start date August 2016) | NCT02813135 |
| A Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination with Metronomic Chemotherapy in Children and Teenagers with Refractory/Relapsing Solid Tumors or Lymphoma | Nivolumab ± cyclophosphamide ± vinblastine ± capecitabine | Solid tumors, lymphoma | 1/2 | 102 | Accruing (Start date September 2018) | NCT03585465 |
| A Phase I Study of 131-1 Meta-iodobenzylguanidine (mIBG) Followed by Nivolumab and Chimeric 14.18 Anti-GD2 Monoclonal Antibody Produced in Chinese Hamster Ovary Cells (ch14.18/CHO) in Children With Relapsed/Refractory Neuroblastoma | Nivolumab | Neuroblastoma | 1 | 36 | Accruing (Start date May 2018) | NCT02914405 |
| A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051) | Pembrolizumab | Melanoma, lymphoma, solid tumors, classical Hodgkin lymphoma, microsatellite-instability-high solid tumor | 1/2 | 310 | Accruing (Start date March 2015) | NCT02332668 |
| A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors | Durvalumab | Solid tumors, lymphoma, CNS tumors | 1 | 36 | Accruing (Start date July 2016) | NCT02793466 |
| A Phase I/II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma | Pidilizumab | Diffuse pontine glioma | 1/2 | 50 | Active, not accruing (Estimated study completion date April 2019) | NCT01952769 |
CNS, central nervous system.
Note: Information on these clinical trials is available at the U.S. National Library of Medicine ClinicalTrials.gov.